Your browser doesn't support javascript.
loading
Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.
Croucher, Peter J P; Ridinger, Maya; Becker, Pamela S; Lin, Tara L; Silberman, Sandra L; Wang, Eunice S; Zeidan, Amer M.
Affiliation
  • Croucher PJP; Cardiff Oncology Inc., 11055 Flintkote Avenue, San Diego, CA, 92121, USA.
  • Ridinger M; Cardiff Oncology Inc., 11055 Flintkote Avenue, San Diego, CA, 92121, USA.
  • Becker PS; Leukemia Division, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, 91010, USA.
  • Lin TL; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas, Kansas City, KS, 66205, USA.
  • Silberman SL; SLS Oncology LLC, Durham, NC, 27713, USA.
  • Wang ES; Leukemia Service, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.
  • Zeidan AM; Yale University and Yale Cancer Center, New Haven, 333 Cedar Street, PO Box 208028, New Haven, CT, 06520-8028, USA. amer.zeidan@yale.edu.
Ann Hematol ; 102(11): 3049-3059, 2023 Nov.
Article in En | MEDLINE | ID: mdl-37702821
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Piperazines / Pyrazoles / Quinazolines / Leukemia, Myeloid, Acute / Spliceosomes Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Year: 2023 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Piperazines / Pyrazoles / Quinazolines / Leukemia, Myeloid, Acute / Spliceosomes Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Year: 2023 Type: Article